Studies have shown that cancer treatment with checkpoint inhibitors can lead to rheumatic and musculoskeletal immune-related adverse events (irAEs), but clear guidance for rheumatologists to manage these events was lacking. An EULAR task force was set up to combine expert opinions on how to manage irAEs without jeopardising the response to the checkpoint inhibitor therapy .
The EULAR task force, consisting of 23 experts, developed 4 over-arching principles and 10 recommendations on the matter . The 4 principles are:
1. irAEs may occur during treatment with checkpoint inhibitors;
2. shared decision-making between patients, oncologists, and rheumatologists is needed;
3. rheumatologists should take an active role in engaging with oncologists when they are managing patients who have musculoskeletal signs and symptoms; and
4. rheumatologists should assist in differential diagnosis and mitigate musculoskeletal symptoms to an accept...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« New nanoparticle promising future agent in RA Next Article
Preliminary findings suggest rozibafusp alfa effective and tolerable in RA »
Table of Contents: EULAR 2020
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.